Literature DB >> 26816916

Valproate Induced Hyperammonemic Delirium.

Anupama Muraleedharan1, Dhanya Sasidharan Palappallil2, Reneega Gangadhar3, Soumitra Das4.   

Abstract

Sodium valproate induced hyperammonaemic delirium with normal liver function tests is a relatively uncommon adverse effect. It may be mistaken for psychosis or worsening of mania leading to wrong diagnosis and improper management. Plasma ammonia levels should be monitored in all patients developing altered mental status after receiving valproate therapy. This is a case series of hyperammonaemic delirium due to valproate reported to the Department of Pharmacology from Department of Psychiatry over a period of one year.

Entities:  

Keywords:  Plasma ammonia; Valproate therapy

Year:  2015        PMID: 26816916      PMCID: PMC4717698          DOI: 10.7860/JCDR/2015/15562.6883

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  20 in total

1.  Valproate-induced hyperammonaemia.

Authors:  Michele Raja; Antonella Azzoni
Journal:  J Clin Psychopharmacol       Date:  2002-12       Impact factor: 3.153

Review 2.  Hyperammonemia due to valproic acid in the psychiatric setting.

Authors:  Russell B Carr; Kerrie Shrewsbury
Journal:  Am J Psychiatry       Date:  2007-07       Impact factor: 18.112

3.  Carnitine for valproic acid-induced hyperammonemia.

Authors:  W N Raby
Journal:  Am J Psychiatry       Date:  1997-08       Impact factor: 18.112

4.  Carbamazepine-associated asterixis and hyperammonemia.

Authors:  M Rivelli; R S el-Mallakh; W H Nelson
Journal:  Am J Psychiatry       Date:  1988-02       Impact factor: 18.112

5.  Hyperammonemia and carnitine deficiency in a patient receiving sulfadiazine and pyrimethamine.

Authors:  G Sekas; H S Paul
Journal:  Am J Med       Date:  1993-07       Impact factor: 4.965

6.  Intravenous ribavirin and hyperammonemia in an immunocompromised patient infected with adenovirus.

Authors:  P Bertrand; A Faro; P Cantwell; A Tzakis
Journal:  Pharmacotherapy       Date:  2000-10       Impact factor: 4.705

Review 7.  Valproate-induced hyperammonemic encephalopathy.

Authors:  Alberto Verrotti; Daniela Trotta; Guido Morgese; Francesco Chiarelli
Journal:  Metab Brain Dis       Date:  2002-12       Impact factor: 3.584

Review 8.  Valproate-associated hyperammonemic encephalopathy.

Authors:  Jim Wadzinski; Ronald Franks; David Roane; Max Bayard
Journal:  J Am Board Fam Med       Date:  2007 Sep-Oct       Impact factor: 2.657

9.  Hyperammonemia after transurethral resection of the prostate: a report of 2 cases.

Authors:  K W Ryder; J F Olson; R J Kahnoski; R C Karn; T O Oei
Journal:  J Urol       Date:  1984-11       Impact factor: 7.450

10.  Hepatic and renal contributions to valproic acid-induced hyperammonemia.

Authors:  A M Marini; B S Zaret; R R Beckner
Journal:  Neurology       Date:  1988-03       Impact factor: 9.910

View more
  3 in total

1.  The Menacing Side of Valproate: A Case Series of Valproate-induced Hyperammonemia.

Authors:  Deeksha Elwadhi; Rashmi Prakash; Manushree Gupta
Journal:  Indian J Psychol Med       Date:  2017 Sep-Oct

2.  Valproate induced hyperammonemic encephalopathy treated by haemodialysis.

Authors:  Vinay Singh Chauhan; Siddarth Dixit; Sunil Goyal; Sudip Azad
Journal:  Ind Psychiatry J       Date:  2017 Jan-Jun

3.  Levocarnitine for valproate-induced hyperammonemia in the psychiatric setting: A case series and literature review.

Authors:  Lauren M Brown; Nicole Cupples; Troy A Moore
Journal:  Ment Health Clin       Date:  2018-04-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.